Author + information
- Sunao Nakamura,
- Hisao Ogawa,
- Hans Yeo,
- Wasan Udayachalerm,
- Damras Tresukosol and
- Sudaratana Tansuphaswadikul
The aim of this study is to compare the safety and efficacy of Sirolimus (SES), Paclitaxel (PES), EPC capture (ECS), Zotarolimus (ZES–R/Endeavor Resolute), BiolimusA9 (BES) and Everolimus–eluting stent (EES) on the outcome of percutaneous coronary intervention in patients with diabetes mellitus (DM).
A prospective analysis of 2972 patients with DM (808 SES, 720 PES, 299 ECS, 404 ZES–R, 320 BES, 421 EES) in six high volume Asian centers after successful stenting was performed. The study endpoints were 30 days major adverse cardiac events (MACE) and 12, 24 and 36 months target lesion revascularization (TLR) and MACE.
See table for clinical Results.
The use of drug–eluting stents in patient with DM was safe with low acute complication. Patients treated with BES and EES showed lesser rate of restenosis compared with ECS.
|Number of patients||808||720||299||404||320||421|
|Multivessel disease (%)||76.7||72.3||73.6||79.3||75.0||75.1|
|MACE at 30 days (%)||0.7||1.0||1.0||1.0||0.9||0.5|
|Lesion length (mean: mm)||25.4||23.9||26.2||28.3*||29.9*||28.8*|
|Lesion type: % of B2, C (%)||42.6||47.5||48.8||54.5||52.8||52.5|
|RD at baseline (mean: mm)||2.75||2.69||2.70||2.73||2.70||2.69|
|12 months MLD (mean: mm)||2.51||2.34||2.00||2.52||2.56||2.55|
|36 months MLD (mean: mm)||2.28||2.28||1.70||2.30||2.44||2.39|
RD: reference diameter
↵* p<0.05 vs. ECS.
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.–10:45 a.m.
Session Title: Coronary Stents
Abstract Category: 43. TCT@ACC–i2: Complex Patients, Diabetes, Renal Insufficiency
Presentation Number: 2101–254
- 2013 American College of Cardiology Foundation